Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
74.2M
-
Number of holders
-
30
-
Total 13F shares, excl. options
-
17.2M
-
Shares change
-
-1.26M
-
Total reported value, excl. options
-
$8.11M
-
Value change
-
-$764K
-
Number of buys
-
6
-
Number of sells
-
-16
-
Price
-
$0.47
Significant Holders of ENZON PHARMACEUTICALS, INC. - Common Stock, par value $0.01 per share (ENZN) as of Q1 2016
36 filings reported holding ENZN - ENZON PHARMACEUTICALS, INC. - Common Stock, par value $0.01 per share as of Q1 2016.
ENZON PHARMACEUTICALS, INC. - Common Stock, par value $0.01 per share (ENZN) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.2M shares
of 74.2M outstanding shares and own 23.25% of the company stock.
Largest 10 shareholders include ICAHN CARL C (5.9M shares), RENAISSANCE TECHNOLOGIES LLC (3.14M shares), BlackRock Institutional Trust Company, N.A. (2.83M shares), VANGUARD GROUP INC (1.5M shares), UBS Group AG (723K shares), BLACKROCK ADVISORS LLC (674K shares), Connor, Clark & Lunn Investment Management Ltd. (572K shares), JACOBS LEVY EQUITY MANAGEMENT, INC (524K shares), CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM (254K shares), and GEODE CAPITAL MANAGEMENT, LLC (198K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.